Pfizer Arthritis Drug Has Safety Risks, FDA Report Says

Law360, New York (May 7, 2012, 1:35 PM EDT) -- The U.S. Food and Drug Administration said Monday that clinical trials of Pfizer Inc.'s proposed rheumatoid arthritis drug revealed "serious safety concerns," including increased risks of cancer and serious infections, two days before an agency advisory committee meets to evaluate the findings.

Safety data from Phase III and long-term extension studies of Pfizer's drug, known as tofacitinib, showed increased risks of patients developing lymphoma as well as serious infections, according to a briefing document the FDA prepared for its Arthritis Advisory Committee, which will meet on...
To view the full article, register now.